JP2017505811A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505811A5
JP2017505811A5 JP2016565117A JP2016565117A JP2017505811A5 JP 2017505811 A5 JP2017505811 A5 JP 2017505811A5 JP 2016565117 A JP2016565117 A JP 2016565117A JP 2016565117 A JP2016565117 A JP 2016565117A JP 2017505811 A5 JP2017505811 A5 JP 2017505811A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
glyceryl
patient
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565117A
Other languages
English (en)
Japanese (ja)
Other versions
JP6836905B2 (ja
JP2017505811A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/011798 external-priority patent/WO2015109215A1/en
Publication of JP2017505811A publication Critical patent/JP2017505811A/ja
Publication of JP2017505811A5 publication Critical patent/JP2017505811A5/ja
Application granted granted Critical
Publication of JP6836905B2 publication Critical patent/JP6836905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565117A 2014-01-17 2015-01-16 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用 Active JP6836905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461928622P 2014-01-17 2014-01-17
US61/928,622 2014-01-17
PCT/US2015/011798 WO2015109215A1 (en) 2014-01-17 2015-01-16 The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019191224A Division JP2020037558A (ja) 2014-01-17 2019-10-18 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Publications (3)

Publication Number Publication Date
JP2017505811A JP2017505811A (ja) 2017-02-23
JP2017505811A5 true JP2017505811A5 (enExample) 2018-02-22
JP6836905B2 JP6836905B2 (ja) 2021-03-03

Family

ID=53543490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016565117A Active JP6836905B2 (ja) 2014-01-17 2015-01-16 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用
JP2019191224A Pending JP2020037558A (ja) 2014-01-17 2019-10-18 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019191224A Pending JP2020037558A (ja) 2014-01-17 2019-10-18 尿素サイクル障害及び神経変性障害におけるベンゾエート含有組成物の使用

Country Status (16)

Country Link
US (1) US9968582B2 (enExample)
EP (1) EP3094616B1 (enExample)
JP (2) JP6836905B2 (enExample)
CA (1) CA2936548C (enExample)
CY (1) CY1124115T1 (enExample)
DK (1) DK3094616T3 (enExample)
ES (1) ES2853974T3 (enExample)
HR (1) HRP20210361T1 (enExample)
HU (1) HUE053671T2 (enExample)
LT (1) LT3094616T (enExample)
PL (1) PL3094616T3 (enExample)
PT (1) PT3094616T (enExample)
RS (1) RS61611B1 (enExample)
SI (1) SI3094616T1 (enExample)
SM (1) SMT202100074T1 (enExample)
WO (1) WO2015109215A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304923B2 (en) 2017-10-06 2022-04-19 Rush University Medical Center Use of a benzoate containing composition to treat glycine encephalopathy
US11826326B2 (en) * 2017-11-22 2023-11-28 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
AU2020229316A1 (en) * 2019-02-25 2021-09-16 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用
WO2022093922A1 (en) * 2020-10-28 2022-05-05 Rush University Medical Center Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
EP4262781A4 (en) * 2020-12-16 2025-02-12 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
CA3241282A1 (en) * 2021-12-16 2023-06-22 Kalipada PAHAN Benzoic acid salts for treatment of nervous system injuries and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
WO2008083226A2 (en) 2006-12-28 2008-07-10 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate

Similar Documents

Publication Publication Date Title
JP2017505811A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2013505205A5 (enExample)
JP2015057451A5 (enExample)
HRP20221316T1 (hr) Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
JP2016535786A5 (enExample)
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
BR112015010396A2 (pt) terapia de combinação
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
WO2014058979A3 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
JP2014507474A5 (enExample)
MX2015001917A (es) Composiciones farmaceuticas de memantina.
JP2014516535A5 (enExample)
JP2018515506A5 (enExample)
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
JP2016540000A5 (enExample)
JP2014062109A5 (enExample)
BR112012020223A2 (pt) "pélete farmacêutica de fator de crescimento epidérmico administrável por via oral"
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
JP2020536098A5 (enExample)
FI3831385T3 (fi) Pirlindolienantiomeerien mandelaattisuoloja käytettäviksi lääkinnässä
JP2015512948A5 (enExample)